Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 4, p. s406, 2024. DOI: 10.25251/skin.8.supp.406. Disponível em: https://skin.dermsquared.com/skin/article/view/2854. Acesso em: 13 may. 2026.